Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations — United States, 2021
Jason H. Malenfant, Allison Joyce, Mary J. Choi, Caitlin M. Cossaboom, Amy Whitesell, Brian H. Harcourt, Robert L. Atmar, Julie Villanueva, Beth P. Bell, Christine Hahn, Jamie Loehr, Richard T. Davey, Armand Sprecher, Colleen S. Kraft, Trevor Shoemaker, Joel M. Montgomery, Rita F. Helfand, Inger K. Damon, Sharon E. Frey, Wilbur H. Chen
Abstract
On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1).